Alaska Chapter of the American College of Cardiology

Latest in Cardiology from ACC.org

• CLASP IID: Residual MR and Gradient at 1 Year Post M-TEER
  Patients who underwent mitral transcatheter edge-to-edge repair (M-TEER) with an optimal result were more likely to have improved hemodynamics and less likely to experience major adverse events, all-cause mortality, heart failure (HF) hospitalization or reintervention at one year...
• ACC CardiaCast: The Power of the Care Team
  This episode provides a team-based overview of diagnosing and managing acute paroxysmal supraventricular tachycardia (PSVT) across care settings.
• CKD Studies Spotlight GFR Measurement, Finerenone Benefit and Rivaroxaban Risk
  Research presented at the European Renal Association Congress, held June 3-6 in Glasgow, Scotland, highlighted new findings in chronic kidney disease (CKD), including evidence supporting more precise GFR assessment and trial results on finerenone in nondiabetic CKD and rivaroxaban in advanced CKD patients with CV risk factors.
• Follow-Up of FAVOR III Suggests QFR-Guided PCI Improves 5-Year Outcomes
  When compared with angiography guidance, quantitative flow ratio (QFR)-guided PCI improved five-year clinical outcomes with benefits primarily achieved in the first two years, according to a follow-up study of the multicenter, sham-controlled FAVOR III trial published June 10 in JACC.
• Follow-Up of CENTRAL, DIRECT-PLUS Suggests Visceral Fat Reduction Has Lasting Metabolic Health Benefits
  A long-term follow-up of the CENTRAL and DIRECT-PLUS trials published in Circulation suggests that despite long-term weight regain, visceral fat reduction during lifestyle intervention is associated with sustained improvements in metabolic health.